The identification of IL-1 and its downstream targets, MERTK and TREM2, as important mediators of these effects provides further proof of concept that breaking the crosstalk between CH mutant and WT bone marrow cells represents a potential strategy to prevent or treat CVD in patients with CH. Here, MERTK is linked to cyclic hematopoiesis.